NCT03787056: ONCOPRO

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Recruiting now NA Last updated 16 July 2021

What this trial tests

NA trial testing Blood draws in Cancer in 410 participants. Currently enrolling.

Timeline

4 December 2018

Primary endpoint
4 January 2028

4 January 2028

Quick facts

Lead sponsor	Hospices Civils de Lyon
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	410
Start date	4 December 2018
Primary completion	4 January 2028
Estimated completion	4 January 2028
Sites	17 locations across France

Drugs / interventions tested

• Blood draws — full drug profile →

Conditions studied

• Cancer — all drugs for Cancer →
• Breast Cancer — all drugs for Breast Cancer →
• Gastric Cancer — all drugs for Gastric Cancer →
• Renal Cancer — all drugs for Renal Cancer →

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

18 and older, any sex, with Cancer or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric acids during digestion. It is also important for the regulation of cell growth of the gastric mucosal.

In a healthy person, progastrin is not detectable in the peripheral blood. However, progastrin is abnormally released in the blood of patients with different cancers (colorectal, gastric, ovarian, breast, cervix uterus, melanoma…) The gene GAST coding for progastrin is a direct target gene of the WNT/ß-catenin oncogenic pathway. The activation of this oncogenic pathway is an early event in cancer development.

Chronic activation of the WNT/ß-catenin oncogenic pathway occurs in almost all human solid tumors and is a central mechanism in cancer biology that induces cellular proliferation, blocking of differentiation leading to primary tumor growth and metastasis formation.

Progastrin measured in the peripheral blood of patients on treatments, could be a new powerful marker for diagnosis and prognosis at different stages.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting Wnt Signaling in Endometrial Cancer.
   Fatima I, Barman S, Rai R, Thiel KWW, et al · · 2021 · cited 61× · PMID 34068065 · DOI 10.3390/cancers13102351
2. Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation.
   Tufail M, Jiang CH, Li N. · · 2025 · cited 36× · PMID 40170063 · DOI 10.1186/s12943-025-02306-w
3. Targeting Wnt-β-Catenin Signaling Pathway for Hepatocellular Carcinoma Nanomedicine.
   Bakrania A, To J, Zheng G, Bhat M. · · 2023 · cited 15× · PMID 39130774 · DOI 10.1016/j.gastha.2023.07.012
4. Signalling pathways in a nutshell: from pathogenesis to therapeutical implications in prostate cancer.
   Goncharov AP, Dicusari Elissaiou C, Ben Aharon Farzalla E, Akhvlediani G, et al · · 2025 · cited 2× · PMID 40372974 · DOI 10.1080/07853890.2025.2474175
5. Progastrin: An Overview of Its Crucial Role in the Tumorigenesis of Gastrointestinal Cancers.
   Fioretzaki R, Sarantis P, Charalampakis N, Christofidis K, et al · · 2024 · cited 2× · PMID 38672239 · DOI 10.3390/biomedicines12040885
6. Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study.
   You B, Couraud S, Ceruse P, Badet L, et al · · 2025 · cited 1× · PMID 40598473 · DOI 10.1186/s40364-025-00793-z